Vivo Capital LLC Sells 298,770 Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

Vivo Capital LLC lessened its stake in Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Free Report) by 36.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 520,505 shares of the biotechnology company's stock after selling 298,770 shares during the period. Alpine Immune Sciences comprises 1.6% of Vivo Capital LLC's portfolio, making the stock its 15th biggest holding. Vivo Capital LLC owned approximately 0.79% of Alpine Immune Sciences worth $20,794,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Decheng Capital LLC acquired a new stake in Alpine Immune Sciences during the fourth quarter worth $135,007,000. Decheng Capital Management III Cayman LLC acquired a new stake in shares of Alpine Immune Sciences during the 3rd quarter valued at about $76,810,000. Great Point Partners LLC increased its stake in Alpine Immune Sciences by 20.3% in the fourth quarter. Great Point Partners LLC now owns 3,703,433 shares of the biotechnology company's stock valued at $70,587,000 after acquiring an additional 624,800 shares during the period. Frazier Life Sciences Management L.P. raised its position in Alpine Immune Sciences by 4.9% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 3,131,008 shares of the biotechnology company's stock worth $59,677,000 after purchasing an additional 145,251 shares in the last quarter. Finally, Commodore Capital LP lifted its stake in Alpine Immune Sciences by 21.5% during the fourth quarter. Commodore Capital LP now owns 1,610,000 shares of the biotechnology company's stock worth $30,687,000 after purchasing an additional 285,000 shares during the period. 75.17% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ALPN has been the topic of several analyst reports. Wedbush lowered Alpine Immune Sciences from an "outperform" rating to a "neutral" rating in a research note on Thursday, April 11th. HC Wainwright cut Alpine Immune Sciences from a "buy" rating to a "neutral" rating in a report on Thursday, April 11th. Leerink Partnrs lowered shares of Alpine Immune Sciences from an "outperform" rating to a "market perform" rating in a report on Thursday, April 11th. Royal Bank of Canada reissued a "sector perform" rating and set a $65.00 price target (up from $41.00) on shares of Alpine Immune Sciences in a report on Thursday, April 11th. Finally, Morgan Stanley restated an "equal weight" rating and issued a $65.00 price target (up from $47.00) on shares of Alpine Immune Sciences in a research report on Thursday, April 11th. Eight analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $50.33.

Alpine Immune Sciences Stock Performance

ALPN traded down $0.06 during mid-day trading on Friday, reaching $64.56. The stock had a trading volume of 1,328,666 shares, compared to its average volume of 4,241,909. The firm's fifty day simple moving average is $43.56 and its two-hundred day simple moving average is $26.74. The stock has a market capitalization of $4.23 billion, a P/E ratio of -100.88 and a beta of 1.14. Alpine Immune Sciences, Inc. has a 52 week low of $6.71 and a 52 week high of $64.70.

Alpine Immune Sciences (NASDAQ:ALPN - Get Free Report) last posted its quarterly earnings results on Monday, March 18th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.47. The business had revenue of $30.85 million for the quarter, compared to analysts' expectations of $6.90 million. Alpine Immune Sciences had a negative return on equity of 15.54% and a negative net margin of 54.66%. As a group, analysts expect that Alpine Immune Sciences, Inc. will post -1.74 EPS for the current fiscal year.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.